Skip to Content
Merck
  • c-JUN inhibits mTORC2 and glucose uptake to promote self-renewal and obesity.

c-JUN inhibits mTORC2 and glucose uptake to promote self-renewal and obesity.

iScience (2022-05-24)
Raphael Serna, Ambika Ramrakhiani, Juan Carlos Hernandez, Chia-Lin Chen, Chad Nakagawa, Tatsuya Machida, Ratna B Ray, Xiaohang Zhan, Stanley M Tahara, Keigo Machida
ABSTRACT

Metabolic syndrome is associated with obesity, insulin resistance, and the risk of cancer. We tested whether oncogenic transcription factor c-JUN metabolically reprogrammed cells to induce obesity and cancer by reduction of glucose uptake, with promotion of the stemness phenotype leading to malignant transformation. Liquid alcohol, high-cholesterol, fat diet (HCFD), and isocaloric dextrin were fed to wild-type or experimental mice for 12 months to promote hepatocellular carcinoma (HCC). We demonstrated 40% of mice developed liver tumors after chronic HCFD feeding. Disruption of liver-specific c-Jun reduced tumor incidence 4-fold and improved insulin sensitivity. Overexpression of c-JUN downregulated RICTOR transcription, leading to inhibition of the mTORC2/AKT and glycolysis pathways. c-JUN inhibited GLUT1, 2, and 3 transactivation to suppress glucose uptake. Silencing of RICTOR or c-JUN overexpression promoted self-renewal ability. Taken together, c-JUN inhibited mTORC2 via RICTOR downregulation and inhibited glucose uptake via downregulation of glucose intake, leading to self-renewal and obesity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cycloheximide, High Purity, Antifungal antibiotic that inhibits protein synthesis in eukaryotes but not in prokaryotes.